MCID: DYS021
MIFTS: 45

Dysautonomia

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Eye diseases, Skin diseases

Aliases & Classifications for Dysautonomia

MalaCards integrated aliases for Dysautonomia:

Name: Dysautonomia 51 29 52 69

Classifications:



Summaries for Dysautonomia

NINDS : 51 Dysautonomia refers to a disorder of autonomic nervous system (ANS) function that generally involves failure of the sympathetic or parasympathetic components of the ANS, but dysautonomia involving excessive or overactive ANS actions also can occur. Dysautonomia can be local, as in reflex sympathetic dystrophy, or generalized, as in pure autonomic failure. It can be acute and reversible, as in Guillain-Barre syndrome, or chronic and progressive. Several common conditions such as diabetes and alcoholism can include dysautonomia. Dysautonomia also can occur as a primary condition or in association with degenerative neurological diseases such as Parkinson's disease. Other diseases with generalized, primary dysautonomia include multiple system atrophy and familial dysautonomia. Hallmarks of generalized dysautonomia due to sympathetic failure are impotence (in men) and a fall in blood pressure during standing (orthostatic hypotension). Excessive sympathetic activity can present as hypertension or a rapid pulse rate.

MalaCards based summary : Dysautonomia is related to parkinson disease 1 and dysautonomia, familial. An important gene associated with Dysautonomia is ELP1 (Elongator Complex Protein 1), and among its related pathways/superpathways are Neuroscience and Parkinsons Disease Pathway. The drugs Dopamine and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include heart, spinal cord and brain, and related phenotypes are Decreased telomerase activity and no phenotypic analysis

Wikipedia : 72 Dysautonomia or autonomic dysfunction is a condition in which the autonomic nervous system (ANS) does... more...

Related Diseases for Dysautonomia

Diseases in the Dysautonomia family:

Dysautonomia, Familial Dysautonomia Like Disorder

Diseases related to Dysautonomia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 165)
id Related Disease Score Top Affiliating Genes
1 parkinson disease 1 31.1 PRKN SNCA
2 dysautonomia, familial 12.4
3 dysautonomia like disorder 11.9
4 motor neuropathy, peripheral, with dysautonomia 11.8
5 acute cholinergic dysautonomia 11.7
6 pure autonomic failure 11.7
7 autonomic dysfunction 11.5
8 insensitivity to pain, congenital, with anhidrosis 11.5
9 orthostatic intolerance 11.0
10 stuve-wiedemann syndrome/schwartz-jampel type 2 syndrome 10.9
11 insensitivity to pain, congenital 10.8
12 neuropathy, hereditary sensory and autonomic, type vi 10.8
13 parkinson disease, late-onset 10.7
14 rigidity and multifocal seizure syndrome, lethal neonatal 10.7
15 parkinson disease 23, autosomal recessive, early onset 10.7
16 insomnia, fatal familial 10.7
17 autoimmune autonomic ganglionopathy 10.7
18 autoimmune gastrointestinal dysmotility 10.7
19 primary orthostatic hypotension 10.7
20 postural hypotension 10.7
21 nephronophthisis 2, infantile 10.3 ACTL7B ELP1
22 parkinson disease 10 10.2 PRKN SNCA
23 celiac disease 12 10.2 PRKN SNCA
24 sparc-related osteogenesis imperfecta 10.2 PRKN SNCA
25 waldenstroem's macroglobulinemia 10.1 PRKN SNCA
26 13q12.3 microdeletion syndrome 10.1 DNAJC13 SNCA
27 mast syndrome 10.1 PRKN SNCA
28 neuropathy 10.1
29 ectodermal dysplasia 13, hair/tooth type 10.1 PRKN SNCA
30 brain injury 10.1
31 supranuclear palsy, progressive atypical 10.1 PRKN SNCA
32 traumatic brain injury 10.0
33 thyrotropin-releasing hormone deficiency 10.0 PRKN SNCA
34 neuronitis 10.0
35 autonomic neuropathy 9.9
36 ganglioneuroma 9.9 PRKN SNCA
37 pupil disease 9.8 NTRK1 SNCA
38 febrile seizures, familial, 3b 9.8 ELP1 NTRK1
39 multiple system atrophy 9.8
40 polyneuropathy 9.8
41 parietal foramina 3 9.8 PRKN SNCA
42 leprosy 9.7
43 myopathy 9.7
44 syncope 9.7
45 fissured tongue 9.7 ELP1 NTRK1
46 esophagitis 9.7
47 chagas disease 9.7
48 cerebritis 9.7
49 chronic fatigue syndrome 9.7
50 dopamine beta-hydroxylase deficiency 9.6

Graphical network of the top 20 diseases related to Dysautonomia:



Diseases related to Dysautonomia

Symptoms & Phenotypes for Dysautonomia

GenomeRNAi Phenotypes related to Dysautonomia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased telomerase activity GR00156-A 8.62 ELP1 NTRK1

MGI Mouse Phenotypes related to Dysautonomia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 no phenotypic analysis MP:0003012 8.92 ELP1 NTRK1 PRKN SNCA

Drugs & Therapeutics for Dysautonomia

Drugs for Dysautonomia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 489)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
2
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
3
Zolpidem Approved Phase 4 82626-48-0 5732
4 Zotepine Approved Phase 4 26615-21-4
5
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
6
Acetylcholine Approved Phase 4 51-84-3 187
7
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
8
Midodrine Approved Phase 4,Phase 3,Phase 2,Phase 1 133163-28-7, 42794-76-3 4195
9
Metoprolol Approved, Investigational Phase 4,Phase 2,Phase 1 37350-58-6, 51384-51-1 4171
10
Bupivacaine Approved, Investigational Phase 4,Phase 3 2180-92-9, 38396-39-3 2474
11
Triamcinolone Approved, Vet_approved Phase 4,Phase 3 124-94-7 31307
12
Levodopa Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-92-7 6047
13
Propranolol Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1 525-66-6 4946
14
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 1
15
Fludrocortisone Approved Phase 4,Phase 1 127-31-1 31378
16
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
17
Droxidopa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23651-95-8 443940
18
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
19
Bisoprolol Approved Phase 4 66722-44-9 2405
20 tannic acid Approved, Nutraceutical Phase 4
21
Vitamin C Approved, Nutraceutical Phase 4,Phase 3,Early Phase 1 50-81-7 5785 54670067
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
23
gamma-Aminobutyric acid Investigational Phase 4 56-12-2 119
24 Antipsychotic Agents Phase 4,Phase 3
25 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Dopamine Antagonists Phase 4,Phase 3,Phase 1
28 GABA Agents Phase 4,Early Phase 1
29 GABA Agonists Phase 4
30 GABA-A Receptor Agonists Phase 4
31 Hypnotics and Sedatives Phase 4,Phase 1,Early Phase 1
32 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34
Serotonin Phase 4,Phase 2,Phase 1,Early Phase 1 50-67-9 5202
35 Serotonin Agents Phase 4,Phase 2,Phase 1,Early Phase 1
36 Serotonin Antagonists Phase 4
37 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Dopamine agonists Phase 4,Phase 1
39 N 0437 Phase 4
40 abobotulinumtoxinA Phase 4
41 Botulinum Toxins Phase 4
42 Botulinum Toxins, Type A Phase 4
43 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Neuromuscular Agents Phase 4
45 onabotulinumtoxinA Phase 4
46 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
48 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Adrenergic Antagonists Phase 4,Phase 2,Phase 1,Early Phase 1
50 Adrenergic beta-Antagonists Phase 4,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 487)

id Name Status NCT ID Phase Drugs
1 Risperidone and Zotepine in the Treatment of Delirium Unknown status NCT00622011 Phase 4 Risperidone and Zolpidem for delirium
2 Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome Unknown status NCT01823770 Phase 4 Rotigotine;Placebo patchs
3 Closed Loop Stimulation for Neuromediated Syncope (SPAIN Study) Unknown status NCT01621464 Phase 4
4 Botulinum A Toxin in Patients With Parkinson's Disease Unknown status NCT00822913 Phase 4 Intravesical injection of Botulinum A toxin
5 Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI Unknown status NCT02298660 Phase 4 BOTOX
6 Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's Disease Completed NCT00914134 Phase 4 Levodopa infusion
7 Heart Rate Variability in Fibromyalgia - Effects of Strengthening Exercises Completed NCT02004405 Phase 4
8 Propranolol to Treat Fainting Due to Sympathoadrenal Imbalance Completed NCT00060866 Phase 4 Propranolol
9 Sympathetic Heart Innervation in Patients With Tako-Tsubo Cardiomyopathy Completed NCT01524861 Phase 4 Placebo;alpha-lipoic acid;L-acetyl carnitine
10 Prophylactic Administration of Vitamin C in Wrist Fractures Completed NCT00296868 Phase 4 ascorbic acid (vitamin C) versus placebo
11 Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study Completed NCT02308124 Phase 4 Midodrine;Pyridostigmine Bromide;Midodrine + pyridostigmine
12 Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01518946 Phase 4 Midodrine HCl;Placebo
13 Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01515865 Phase 4 Midodrine HCl;Placebo
14 Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension Completed NCT00555880 Phase 4 Midodrine hydrochloride;Placebo
15 A Study for Patients With Neurogenic Orthostatic Hypotension Completed NCT00046475 Phase 4 Midodrine Hydrochloride
16 Clinical Trial for the Prevention of Vasovagal Syncope Completed NCT00118482 Phase 4 fludrocortisone acetate
17 Restore Claims Characterization Study Completed NCT00200122 Phase 4
18 High Frequency Stimulation Trials in Patients With Precision Spinal Cord Stimulator System Completed NCT02265848 Phase 4
19 A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
20 Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension Recruiting NCT02586623 Phase 4 Droxidopa capsules;Placebo capsules
21 Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor Recruiting NCT03178591 Phase 4 vildagliptin;Dapagliflozin
22 Dawn Simulation and Postural Hypotension Recruiting NCT02632318 Phase 4
23 Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Recruiting NCT02123056 Phase 4 Metoprolol;Matching Placebo
24 Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV Recruiting NCT01456481 Phase 4 midodrine hydrochloride;matching placebo
25 Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors Active, not recruiting NCT03098368 Phase 4 Rotigotine;Placebo
26 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
27 Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS) Active, not recruiting NCT02171988 Phase 4 Propranolol;Bisoprolol;Propranolol+pyridostigmine;Bisoprolol+pyridostgmine
28 Brain Perfusion & Oxygenation in Parkinson's Disease With NOH Not yet recruiting NCT03229174 Phase 4 Droxidopa;Placebo
29 Tolerability of Suprascapular and Median Nerve Blocks for the Treatment of Shoulder-hand Syndrome Not yet recruiting NCT03291197 Phase 4 Suprascapular and median nerve blocks
30 Autonomic Dysfunction and Spinal Cord Stimulation in Complex Regional Pain Syndrome Terminated NCT00780390 Phase 4
31 A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension Terminated NCT00046163 Phase 4 midodrine hydrochloride (ProAmatine®)
32 A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients Unknown status NCT01314625 Phase 3
33 Post-Exercise Hypotension in Elderly Hypertensive Men Unknown status NCT02415582 Phase 3
34 Clinical Trial on the Effectiveness of Traditional Chinese Medicinal Mixture in Parkinson Disease Unknown status NCT00629161 Phase 2, Phase 3 Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant);placebo
35 Surgical Treatment Of Complex Regional Pain Syndrome Type II (CRPS II) Unknown status NCT01392599 Phase 3
36 Acupuncture for Post-stroke Shoulder-hand Syndrome Unknown status NCT02011854 Phase 2, Phase 3
37 RCT :Thoracic Sympathetic Block for the Treatment of Complex Regional Pain Syndrome I of the Upper Limb Unknown status NCT01612364 Phase 3
38 Analysis of Photoplethysmographic Signal in Lumbar Sympathetic Block Unknown status NCT01134289 Phase 3
39 Intravenous Immunoglobulins in Complex-regional Pain Syndrome Unknown status NCT00949065 Phase 3
40 The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia Completed NCT01987219 Phase 3 Albuterol-sulphate;Ipratropium-bromide
41 Carbidopa for the Treatment of Nausea and Vomiting in Familial Dysautonomia Completed NCT01212484 Phase 3 Carbidopa;Placebo
42 Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis Completed NCT00409175 Phase 2, Phase 3 Fx-1006A;Placebo
43 The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury Completed NCT02099890 Phase 3
44 Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy Completed NCT01522235 Phase 2, Phase 3 Double blinded IVIg
45 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304) Completed NCT01132326 Phase 3 Droxidopa
46 A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa Completed NCT00782340 Phase 3 Placebo;Droxidopa
47 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00633880 Phase 3 Placebo;Droxidopa
48 Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00738062 Phase 3 Droxidopa;Placebo
49 Clinical Trial on the Effectiveness of Herbal Medicinal Mixture in Parkinson Disease Completed NCT00656253 Phase 2, Phase 3 Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.);Placebo
50 Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach Completed NCT02008721 Phase 3 EGCG as putative neuroprotective agent;Placebo

Search NIH Clinical Center for Dysautonomia

Genetic Tests for Dysautonomia

Genetic tests related to Dysautonomia:

id Genetic test Affiliating Genes
1 Dysautonomia 29

Anatomical Context for Dysautonomia

MalaCards organs/tissues related to Dysautonomia:

39
Heart, Spinal Cord, Brain, Testes, Liver, Cortex, Bone

Publications for Dysautonomia

Articles related to Dysautonomia:

(show top 50) (show all 608)
id Title Authors Year
1
Transient dysautonomia in an acute phase of encephalopathy with biphasic seizures and late reduced diffusion. ( 28413125 )
2017
2
Partial dysautonomia: An interesting presentation. ( 28749384 )
2017
3
Animal and cellular models of familial dysautonomia. ( 28667575 )
2017
4
Alterations in amino acid status in cats with feline dysautonomia. ( 28333983 )
2017
5
Intranasal dexmedetomidine for adrenergic crisis in familial dysautonomia. ( 28674865 )
2017
6
BGP-15 prevents the death of neurons in a mouse model of familial dysautonomia. ( 28439028 )
2017
7
Calming the Storm: Dysautonomia for the Pediatrician. ( 28716515 )
2017
8
Sudden Unexpected Death During Sleep in Familial Dysautonomia: A Case-Control Study. ( 28521050 )
2017
9
Pathological Confirmation of Optic Neuropathy in Familial Dysautonomia. ( 28395083 )
2017
10
Pyridoxine Toxicity Small Fiber Neuropathy With Dysautonomia: A Case Report. ( 28827489 )
2017
11
Ipilimumab-induced Guillain-BarrAc Syndrome Presenting as Dysautonomia: An Unusual Presentation of a Rare Complication of Immunotherapy. ( 28452849 )
2017
12
RBM24 promotes U1 snRNP recognition of the mutated 5' splice site in the IKBKAP gene of familial dysautonomia. ( 28592461 )
2017
13
Familial dysautonomia: a disease with hidden tears. ( 28401297 )
2017
14
Proteasome inhibitors to alleviate aberrant IKBKAP mRNA splicing and low IKAP/hELP1 synthesis in familial dysautonomia. ( 28404519 )
2017
15
Response Letter to 'Optimising physiology for adolescents with dysautonomia'. ( 28906019 )
2017
16
Pure autonomic failure versus prodromal dysautonomia in Parkinsona89s disease: Insights from the bedside. ( 28164144 )
2017
17
Methotrexate-induced dysautonomia in a patient with rheumatoid arthritis. ( 28398506 )
2017
18
Use of Biotronik closed loop pacemaker to treat recurrent syncope in pediatric patient with dysautonomia. ( 28491761 )
2017
19
Optimising physiology for adolescents with dysautonomia. ( 28477426 )
2017
20
Basic research and model systems in familial dysautonomia: What do we know and what's next? ( 28707017 )
2017
21
Twenty-four-hour blood pressure profile, orthostatic hypotension, and cardiac dysautonomia in elderly type 2 diabetic hypertensive patients. ( 27624333 )
2016
22
Prominent dysautonomia in a patient with POEMS syndrome. ( 27165541 )
2016
23
Familial Dysautonomia: Mechanisms and Models. ( 27561110 )
2016
24
Cerebral autoregulation and symptoms of orthostatic hypotension in familial dysautonomia. ( 27613312 )
2016
25
Poster 72 Teetering on the Edge: Rehabilitation in a Medically Complex Patient with Familial Dysautonomia (Hereditary Sensory Autonomic Neuropathy Type III): A Case Report. ( 27672840 )
2016
26
Dysautonomia Differentially Influences the Effect of Affective Pain Perception on Quality of Life in Parkinson's Disease Patients. ( 27239367 )
2016
27
Tocotrienol Treatment in Familial Dysautonomia: Open-Label Pilot Study. ( 27129499 )
2016
28
Poster 257 Tizanidine Reduces Night Sweats due to Dysautonomia in Syringomyelia: A Case Report. ( 27673012 )
2016
29
Axon Transport and Neuropathy: Relevant Perspectives on the Etiopathogenesis of Familial Dysautonomia. ( 26724390 )
2016
30
Sensory and autonomic deficits in a new humanized mouse model of familial dysautonomia. ( 26769677 )
2016
31
Human papilloma virus vaccination and dysautonomia: Considerations for autoantibody evaluation and HLA typing. ( 27553747 )
2016
32
Obstructive Sleep Disordered Breathing Is More Common than Central in Mild Familial Dysautonomia. ( 27655467 )
2016
33
MicroRNA screening identifies a link between NOVA1 expression and a low level of IKAP in familial dysautonomia. ( 27483351 )
2016
34
Body weight and dysautonomia in early Parkinson's disease. ( 27357472 )
2016
35
Mother-induced hypertension in familial dysautonomia. ( 26589199 )
2016
36
Dysautonomia in prodromal I+-synucleinopathy: peripheral versus central autonomic degeneration. ( 26842960 )
2016
37
Psychiatric manifestations and dysautonomia at the onset of focal epilepsy in adults: Clinical signs indicating autoimmune origin. ( 27311973 )
2016
38
Familial dysautonomia: History, genotype, phenotype and translational research. ( 27317387 )
2016
39
Serum catecholamines and dysautonomia in diabetic gastroparesis and liver cirrhosis. ( 26181082 )
2015
40
Early dysautonomia detected by heart rate variability predicts late depression in female patients following mild traumatic brain injury. ( 26560198 )
2015
41
Hypothesis: Human papillomavirus vaccination syndrome--small fiber neuropathy and dysautonomia could be its underlying pathogenesis. ( 25990003 )
2015
42
Lower urinary tract dysfunction in patients with dysautonomia. ( 26530163 )
2015
43
Balance training using an iPhone application in people with familial dysautonomia: three case reports. ( 25504486 )
2015
44
Contemporary perioperative management of adult familial dysautonomia (riley-day syndrome). ( 25909774 )
2015
45
Complex regional pain syndrome and dysautonomia in a 14-year-old girl responsive to therapeutic plasma exchange. ( 26011726 )
2015
46
Brainstem reflexes in familial dysautonomia. Reply to "Evidence of brainstem dysfunction in patients with familial dysautonomia and carriers of the IKBKAP mutation". ( 26529998 )
2015
47
Increased frequency of rhabdomyolysis in familial dysautonomia. ( 26202308 )
2015
48
Canine dysautonomia in a litter of Havanese puppies. ( 26179098 )
2015
49
TECPR2 mutations cause a new subtype of familial dysautonomia like hereditary sensory autonomic neuropathy with intellectual disability. ( 26542466 )
2015
50
Laughter is not always funny: breath-holding spells in familial dysautonomia. ( 25539948 )
2015

Variations for Dysautonomia

Expression for Dysautonomia

Search GEO for disease gene expression data for Dysautonomia.

Pathways for Dysautonomia

Pathways related to Dysautonomia according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.64 NTRK1 PRKN SNCA
2 11.08 PRKN SNCA
3 10.13 PRKN SNCA

GO Terms for Dysautonomia

Cellular components related to Dysautonomia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 early endosome GO:0005769 8.8 DNAJC13 NTRK1 TMEM230

Biological processes related to Dysautonomia according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of protein phosphorylation GO:0001933 9.51 PRKN SNCA
2 adult locomotory behavior GO:0008344 9.49 PRKN SNCA
3 protein destabilization GO:0031648 9.48 PRKN SNCA
4 regulation of reactive oxygen species metabolic process GO:2000377 9.46 PRKN SNCA
5 regulation of dopamine secretion GO:0014059 9.43 PRKN SNCA
6 negative regulation of neuron apoptotic process GO:0043524 9.43 NTRK1 PRKN SNCA
7 synaptic transmission, dopaminergic GO:0001963 9.4 PRKN SNCA
8 regulation of neurotransmitter secretion GO:0046928 9.37 PRKN SNCA
9 dopamine metabolic process GO:0042417 9.32 PRKN SNCA
10 synaptic vesicle transport GO:0048489 9.16 SNCA TMEM230
11 dopamine uptake involved in synaptic transmission GO:0051583 8.96 PRKN SNCA
12 negative regulation of neuron death GO:1901215 8.8 NTRK1 PRKN SNCA

Molecular functions related to Dysautonomia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 kinase binding GO:0019900 9.16 NTRK1 PRKN
2 Hsp70 protein binding GO:0030544 8.96 PRKN SNCA
3 phospholipase binding GO:0043274 8.62 PRKN SNCA

Sources for Dysautonomia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....